A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PV / polycythemia vera

[Related PubMed/MEDLINE]
Total Number of Papers: 1362
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PV  (>> Co-occurring Abbreviation)
Long Form:   polycythemia vera
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2016 Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. ET, NAP
2016 Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. CI, ET, HT, MPN
2016 Idiopathic erythrocytosis: a study of a large cohort with a long follow-up. FE, IE
2016 Management of polycythaemia vera: a critical review of current data. ---
2016 Masked polycythaemia vera: presenting features, response to treatment and clinical outcomes. BCSH
2016 Myeloproliferative neoplasms: A decade of discoveries and treatment advances. CALR, CML, ET, MPL, MPN, PMF, WHO
2016 Myeloproliferative neoplasms: Current molecular biology and genetics. ASXL1, CALR, CBL, DNMT3A, ET, EZH2, HMGA2, IKZF1, MPNs, Ph-MPNs, PMF, SOCS, TET2, TP53
2016 Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study. AER, SEER, SIR, SPM
2016 Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. HU, MPN, SAF, TSS
10  2015 A rapid, highly accurate method for quantifying CALR mutant allele burden in persons with myeloproliferative neoplasms. CALR, CML, ET, HES, MPNs, PMF
11  2015 Acute Non-Atherosclerotic ST-Segment Elevation Myocardial Infarction in an Adolescent with Concurrent Hemoglobin H-Constant Spring Disease and Polycythemia Vera. STEMI
12  2015 Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. HU
13  2015 Analysis of JAK2(V617F) mutation in Jordanian patients with myeloproliferative neoplasms. ET, IMF, MPNs
14  2015 Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera. ET, MIAs
15  2015 Association of the ACE I/D gene polymorphisms with JAK2V617F-positive polycythemia vera and essential thrombocythemia. CG, CI, ET, OR, TG
16  2015 BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms. ET, Ph- MPN, PMF
17  2015 Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. AML, ET, MF
18  2015 CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. APMF, ET, MPN-U, MPNs, PMF
19  2015 Calreticulin exon 9 mutations in myeloproliferative neoplasms. CALR, ET, JAK2, MPL, MPNs, PMF
20  2015 Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. CALR, cloud-like, ECMP, EMGM, ET, MF, MPN, PMGM, PVSG
21  2015 Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. ET, MPNs, PMF
22  2015 Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. ET, JAK2, MPNs, Ph, PMF
23  2015 Concurrent Ruptured Pseudoaneurysm of the Internal Carotid Artery and Cerebral Infarction as an Initial Manifestation of Polycythemia Vera. ICA
24  2015 Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. ET, MF
25  2015 Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk? CAD, CFR, ET
26  2015 Current and future treatment options for polycythemia vera. JAK2
27  2015 Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms. CML, ET, MPN, PMF, SM
28  2015 Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. ET, MPNs, PMF, SVT
29  2015 Distribution of lymphocyte subpopulations in patients with polycythemia vera. NK
30  2015 Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. 3'UTR, ET, HMGA2, MPNs, PMF
31  2015 Endovascular stent graft repair of thoracic aortic mural thrombus in a patient with polycythemia vera: a word of caution. TAMT
32  2015 Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice. BM, ET
33  2015 Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group. HU, IFN
34  2015 Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings. ET, miRNA
35  2015 Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features. BM, ET, FCI, MDS, MPN, MPN-U, PMF
36  2015 From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. ET, MF, MPNs, Ph
37  2015 Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. AML, CMML, CN-LOH, ET, MC, MDS/MPN, MF, MPN, MPN-U, SNP-A
38  2015 Hyperbaric oxygen therapy in treating post-ischemic pain caused by polycythemia vera complications: a case report. ---
39  2015 Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. ET, JAK, MF, PMF
40  2015 Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. post-PV MF
41  2015 Influence of the JAK2 V617F Mutation and Inherited Thrombophilia on the Thrombotic Risk among Patients with Myeloproliferative Disorders. ET, PMI, RR
42  2015 JAK-2 V617F mutation increases heparanase procoagulant activity. CML, ET, PMF, TF, TFPI
43  2015 JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients. CMPNs, ET, PMF
44  2015 JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice. MPN, PPMF, PTMF
45  2015 Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis. ET, MF, MPNs, PMF
46  2015 Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. AML, BCS, ET, MPN, OLT, PMF
47  2015 Management of symptoms in polycythemia vera and essential thrombocythemia patients. ET, MF, MPNs
48  2015 Massive intracardiac thrombosis during coronary artery bypass grafting surgery. ---
49  2015 Matrix Metalloproteinases 2 and 9 Polymorphism in Patients With Myeloproliferative Diseases: A STROBE-Compliant Observational Study. ECM, ET, MMPs, SP
50  2015 Mechanisms of thrombogenesis in polycythemia vera. ---
51  2015 Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. ET, MPNs, PMF
52  2015 MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia. ET, miRNA, PMF
53  2015 MMP2 gene-735 C/T and MMP9 gene -1562 C/T polymorphisms in JAK2V617F positive myeloproliferative disorders. ET, MMPs, MPDs, PCR-RFLP
54  2015 Molecular genetic evaluation of myeloproliferative neoplasms. CML, ET, MPNs, PMF
55  2015 Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. IFN-alpha
56  2015 MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. ET, MF, MPNs
57  2015 Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients. ET, MPN-T
58  2015 Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. MPN, MPN-SAF, PMF
59  2015 Myeloproliferative Neoplasms: A Contemporary Review. ASXL1, CALR, ET, JAK2, MPL, PMF
60  2015 Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: clinical and molecular characterization. ---
61  2015 New Therapeutic Approaches in Polycythemia Vera. JAK
62  2015 No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation. ET, MPN
63  2015 Novel and emerging therapies for the treatment of polycythemia vera. ---
64  2015 Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. ET, HPF, NF-E2, NGFR
65  2015 Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. ET, VKA
66  2015 Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. ---
67  2015 Perioperative blood product administration and thromboembolic events in patients with treated polycythemia vera: a case-control study. CI, OR
68  2015 Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. AVWS, CALR, ET, JAK2, MPL
69  2015 Polycythemia Vera Diagnosed after Esophageal Variceal Rupture. ---
70  2015 Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. ---
71  2015 Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. ET
72  2015 Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. ET, IMF, MPDs, NCI
73  2015 Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. ET, MPNs, PMF
74  2015 Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms. ddPCR, ET, MPNs, PMF, SMF
75  2015 Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. ET, IM, miRs, MPNs
76  2015 Ruxolitinib for the treatment of patients with polycythemia vera. ---
77  2015 Ruxolitinib: A Review in Polycythaemia Vera. JAK, STAT
78  2015 Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells. ET, miRNAs, moRNAs, MPN, PMF, sRNAs
79  2015 Subfoveal Choroidal Thickness Is Associated with Blood Hematocrit Level. SFCT
80  2015 Target hematologic values in the management of essential thrombocythemia and polycythemia vera. ET
81  2015 The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. ET, JAK, MF
82  2015 The JAK2 mutation in myeloproliferative neoplasms: A predictive factor of thrombosis. ET, MPN, PMF
83  2015 The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms. CALR, ET, MF, MPN
84  2015 The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms. MPNs
85  2015 The Role of beta-Catenin in Bcr/Abl Negative Myeloproliferative Neoplasms: An Immunohistochemical Study. ET, IRS, IRSmega, IRSvas, MPNs, PMF
86  2015 Up-regulation of MicroRNA 146b is Associated with Myelofibrosis in Myeloproliferative Neoplasms. CALR, ET, JAK2, MF, miR, miRNA, MPN, PMF
87  2015 [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms]. ET, MPN, PMF
88  2015 [Clinical analysis of 70 cases of polycythemia vera]. LDH
89  2015 [Clinical feature and prognosis analysis of elderly patients with polythemia vera]. ---
90  2015 [JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm]. ET, MPN, PMF
91  2015 [Myeloproliferative neoplasms: pathophysiology and therapeutic strategy]. allo-HSCT, ET, HSCs, MF, MPNs
92  2015 [Research progress of myeloproliferative neoplasms]. allo-ASCT, ET, MPN, PMF
93  2015 [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center]. AML, IFN-alpha, OS, post-PV MF, SMR, WBC
94  2015 [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management]. ET, MPN
95  2014 A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. ASO, B2M, ET, GUSB, PLTs, PMF
96  2014 A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. ET, mPV, WHO
97  2014 A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. JAK2
98  2014 Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? MPN
99  2014 Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. ET, MPNs, TET2
100  2014 Angiogenic activity in the sera of patients with post-kidney transplant erythrocytosis. PTE, VEGF